Starling Oncology, Inc.

Starling Oncology, Inc. (STLN) was formed in 2007, initially as a collection of community oncology practices in southern California. The company has evolved to be a national leader in oncology care, focusing on reducing costs while utilizing clinical best practices and technology. Starling Oncology provides oncology, hematology, specialty infusion, and oral pharmacy services on a fee-for-service basis, and also enrolls patients in clinical trials. A core part of its mission involves partnering with managed care providers and other risk-bearing entities to manage the risk and patient coordination for cancer treatment episodes. This is achieved through gain/loss sharing, capitation, and full delegation contracts at the population level, allowing Starling Oncology to control outpatient treatment for both medical oncology (IV-based infusion therapy) and radiation oncology (radiation therapy using linear accelerator equipment). Starling Oncology treats patients across 17 markets and five states in the United States. Its network includes 65 clinics owned by affiliated physicians and staffed with 116 providers, 81 independently-owned clinics contracted with Starling Oncology's managed services organization, and a contracted network of 198 independent providers unaffiliated with Starling Oncology, particularly where Starling Oncology acts as the fully delegated market manager under a value-based contract. As of December 31, 2025, Starling Oncology managed approximately 2.0 million patients under value-based agreements through this network. The company's Patient Services Fee for Service business line provides medical care for physician services, in-house infusion, radiation, and outpatient blood product transfusions, along with 24/7 patient support.